IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

PUSCEDDU, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.650
NA - Nord America 2.213
AS - Asia 1.992
Continente sconosciuto - Info sul continente non disponibili 269
SA - Sud America 164
AF - Africa 40
OC - Oceania 6
Totale 7.334
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.133
DE - Germania 1.244
CN - Cina 616
SG - Singapore 567
GB - Regno Unito 429
IT - Italia 318
BD - Bangladesh 290
SE - Svezia 170
HK - Hong Kong 154
VN - Vietnam 144
RU - Federazione Russa 129
BR - Brasile 122
FR - Francia 83
IN - India 65
NL - Olanda 62
CA - Canada 59
FI - Finlandia 59
IE - Irlanda 57
ID - Indonesia 31
KR - Corea 25
UA - Ucraina 25
CI - Costa d'Avorio 21
DK - Danimarca 20
AR - Argentina 14
PL - Polonia 14
TR - Turchia 14
BE - Belgio 13
JP - Giappone 12
PK - Pakistan 12
IQ - Iraq 11
CO - Colombia 10
PH - Filippine 9
MX - Messico 8
UZ - Uzbekistan 6
ZA - Sudafrica 6
ES - Italia 5
MY - Malesia 5
AU - Australia 4
CH - Svizzera 4
PE - Perù 4
PT - Portogallo 4
PY - Paraguay 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
AZ - Azerbaigian 3
EC - Ecuador 3
JM - Giamaica 3
JO - Giordania 3
NP - Nepal 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BO - Bolivia 2
CR - Costa Rica 2
KE - Kenya 2
KW - Kuwait 2
MA - Marocco 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
SV - El Salvador 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GF - Guiana Francese 1
GR - Grecia 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MV - Maldive 1
PR - Porto Rico 1
RS - Serbia 1
TG - Togo 1
TN - Tunisia 1
UG - Uganda 1
ZW - Zimbabwe 1
Totale 7.065
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.136
Southend 384
Singapore 321
Ashburn 290
Chandler 236
San Jose 141
Hong Kong 129
Dallas 117
Milan 105
Fairfield 94
Beijing 73
Seattle 68
Council Bluffs 67
Princeton 65
Santa Clara 63
Dearborn 61
Wilmington 59
Dublin 57
New York 57
Houston 52
Ho Chi Minh City 50
Munich 47
Woodbridge 42
Hanoi 40
Los Angeles 39
Ann Arbor 35
Buffalo 35
Lauterbourg 35
Nanjing 33
Jinan 32
Boardman 31
Cambridge 29
Moscow 29
Bengaluru 28
Hefei 28
Helsinki 28
Guangzhou 27
Des Moines 26
Shenyang 26
Changsha 24
Jakarta 23
Abidjan 21
Columbus 19
Toronto 19
The Dalles 17
Hebei 16
Cangzhou 15
Seoul 14
Shanghai 14
Turku 14
Brussels 13
Naples 13
Phoenix 13
Fuzhou 12
Rome 12
Zhengzhou 12
Da Nang 11
Montreal 10
London 9
Tokyo 9
Warsaw 9
Wuhan 9
Hangzhou 8
Mumbai 8
Ottawa 8
Shenzhen 8
São Paulo 8
Tianjin 8
Turin 8
Atlanta 7
Baghdad 7
Chengdu 7
Chicago 7
Fremont 7
Haikou 7
Islamabad 7
Redwood City 7
Rio de Janeiro 7
Central District 6
Eitensheim 6
Jiaxing 6
Nanchang 6
Nuremberg 6
San Diego 6
Andover 5
Berlin 5
Charlotte 5
Erlangen 5
Kent 5
Kunming 5
Madignano 5
Palermo 5
Tashkent 5
Bexley 4
Bologna 4
Brasília 4
Brescia 4
Bühl 4
Bắc Ninh 4
Genoa 4
Totale 4.771
Salva come PNG Salva come JPEG
Nome #
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis 343
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) 322
Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis 302
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers 274
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives 268
Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms 255
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up 251
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. 251
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies 250
Diagnosis and management of typical and atypical lung carcinoids 237
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy : a phase II ITMO study 228
Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum 228
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors 215
Update on medical treatment of small intestinal neuroendocrine tumors 213
Safety profile and treatment response of everolimus in different solid tumors : an observational study 208
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes 203
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer 202
Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs 201
Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver 198
Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037) 196
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors 194
From biology to clinical experience : evolution in the knowledge of neuroendocrine tumours 194
Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors 190
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 176
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors 161
Well-differentiated neuroendocrine tumor of tailgut cyst : A rare entity with controversial medical opportunities 160
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2 157
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 157
Pancreatic well-differentiated neuroendocrine neoplasms (PWDNENS) : What place for everolimus and sunitinib derived from esmo clinical practice guidelines in the therapeutic algorithm? 149
Malignant pheochromocytoma and paraganglioma : future considerations for therapy 148
Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites : Grade, mesenteric tumour deposits and emerging novelties 125
Treatment of lung large cell neuroendocrine carcinoma 119
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options : a systematic review 118
The underestimated role of somatostatin analogs in the NETTER-1 trial 108
The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence 92
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential 90
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 83
Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors 67
null 1
Totale 7.334
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.038
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.038
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022316 0 11 14 17 17 15 26 15 22 65 13 101
2022/2023596 71 85 51 73 51 112 9 32 53 11 40 8
2023/2024997 6 21 21 10 70 21 171 144 72 143 156 162
2024/20251.285 148 169 123 154 60 34 38 83 49 117 79 231
2025/20262.404 224 174 207 161 241 120 276 83 213 146 302 257
2026/2027183 147 36 0 0 0 0 0 0 0 0 0 0
Totale 7.334